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Evidence about electronic cigarettes: a foundation built
on rock or sand?
Public Health England recently endorsed the use of e-cigarettes as an aid to quitting smoking.
Martin McKee and Simon Capewell question the evidence on safety and efficacy underpinning
the recommendations
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Those responsible for safeguarding the health of the public must
often tackle complex and controversial issues. Public Health
England (PHE) has been courageous in entering the debate on
the role of electronic cigarettes in tobacco control. In a new
report it concludes that e-cigarettes are much safer than
conventional cigarettes,1 and one of its author is quoted as
describing them as a potential “game changer” in tobacco
control.2 Media coverage suggests that the debate is now over,
with a BBC correspondent describing the evidence as
“unequivocal.”2 However, although British organisations such
as the Royal College of Physicians of London3 and ASH UK,4
have endorsed some of the report’s conclusions, albeit with
caveats, many others have come to the opposite opinion. These
include the British Medical Association, the UK Faculty of
Public Health, the US Centers for Disease Control and
Prevention, the American Lung Association, the World Health
Organization,5 the European Commission,6 and other leading
international health bodies.7 The available evidence about
e-cigarettes suggests that the debate is far from over and
questions remain about their benefits and harms.
Defining the role of e-cigarettes
Fundamental divisions seem to exist between those engaged in
this debate. Supporters of e-cigarettes focus narrowly on existing
smokers, comparing the devices’ effects with those of smoking
conventional cigarettes. As well as being an aid to quitting,
e-cigarettes are seen as having a role for people who do not
want to quit, offering a safer substitute for some of the cigarettes
they would otherwise smoke.
Meanwhile, those on the other side of the debate express concern
about uptake of e-cigarettes among people, especially children
and adolescents, who would not otherwise smoke and about
their long term health effects. They argue that although
e-cigarettes do not contain some of the most harmful substances
found in conventional cigarettes, such as tar, they do contain
other substances such as formaldehyde (a carcinogen) and
diverse flavourings. Thus, it is equally important to include
non-smoking as a comparator. They also draw attention to
important epidemiological evidence that contrary to what is
widely believed, reduced smoking (as opposed to quitting) may
not reduce overall risk of death.8 The expression “dual use,”
which acknowledges that two thirds of e-cigarette users also
smoke, rarely occurs in the PHE report. Although some dual
use is inevitable during the quitting process, if this persists long
term health concerns remain. A recent cohort study byMcNeill
and colleagues showed that dual use among daily “vapers”
apparently remained above 80% after 12 months follow-up,
which is worrying.9
Quality of the evidence
A fundamental principle of public health is that policies should
be based on evidence of effectiveness. So does the available
evidence show clearly that e-cigarettes are as effective as
established quitting aids? Unfortunately not. The recent
Cochrane review is widely cited,10 but it included only two
randomised controlled trials, both with important limitations,
and concluded that the evidence was of “low or very low quality
by GRADE standards.” The PHE report authors concede the
weakness of the evidence, noting how a single observational
study with substantial limitations offers “some of the best
evidence to date on the effectiveness of e-cigarettes for use in
quit attempts.”
Where there is uncertainty about risks, the precautionary
principle should apply. Thus, in the absence of scientific
consensus that the substance is not harmful to the public, the
burden of proof that it is not harmful falls on those taking an
action. The quality of the evidence cited by PHE therefore
becomes crucial. The headline message from the PHE report,
widely quoted in the media, is that “best estimates show
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e-cigarettes are 95% less harmful to your health than normal
cigarettes,” seemingly leaving little room for uncertainty about
long term risks. Yet a recent systematic review,11which the PHE
report surprisingly fails to cite, came to a different conclusion.
It found serious methodological problems in many of the 76
studies it reviewed, and one third of the studies (34%) were
published by authors with conflicts of interest. The systematic
review also expressed concern about the effects of various
substances in e-cigarettes, some but not all of which are also
found in conventional cigarettes. It concluded that “due to many
methodological problems, severe conflicts of interest, the
relatively few and often small studies, the inconsistencies and
contradictions in results, and the lack of long-term follow-up
no firm conclusions can be drawn on the safety of e-cigarettes.
However, they can hardly be considered harmless.”
We might also expect that the prominently featured “95% less
harmful” figure was based on a detailed review of evidence,
supplemented by modelling. In fact, it comes from a single
meeting of 12 people convened to develop a multicriteria
decision analysis (MCDA) model to synthesise their opinions
on the harms associated with different nicotine containing
products; the results of the meeting were summarised in a
research paper.12 The authors state: “The sponsor of the study
had no role in any stage of the MCDA process or in the writing
of this article, and was not present at the workshop.” However,
given the importance of complete transparency in an area as
controversial as this, it is legitimate to ask about the sponsors.
One is a company called EuroSwiss Health.13An internet search
reveals little about its activities other than that it funded the
meeting, but it is one of several companies registered at the
same address in a village outside Geneva with the same chief
executive. He is reported to have previously received funding
from British American Tobacco (BAT)14 for writing a book on
nicotine as a means of harm reduction,15 although the book states
that “the statements, findings, conclusions and recommendations
contained in the book were developed independently of BAT.”
He also endorsed BAT’s public health credentials in its 2013
sustainability report.16
The paper also acknowledges support from Lega Italiana Anti
Fumo (Italian Anti-Smoking League), whose chief scientific
adviser was one of the 12 people attending the meeting. He
declares funding from an e-cigarette manufacturer but not the
funding he is reported elsewhere to have received previously
from tobacco company Philip Morris International.17 The
rationale for selecting the members of the panel is not provided,
but they include several known e-cigarette champions, some of
whom also declare industry funding in the paper.12 Some others
present at the meeting are not known for their expertise in
tobacco control. The meeting was also attended by the tobacco
lead at PHE. Furthermore, their paper tellingly concedes that
“A limitation of this study is the lack of hard evidence for the
harms of most products on most of the criteria.” However, none
of these links or limitations are discussed in the PHE report.
Uncertainty around harms
The PHE report asserts that the available evidence suggests that
e-cigarettes are not currently re-normalising smoking among
children and young people in the UK. However, this remains a
major concern for health professionals and parents. In England,
experimentation with e-cigarettes among young people is
worrying high, with over one fifth of 11-15 year olds having
ever used e-cigarettes18; 73% of the young people surveyed who
had tried e-cigarettes were non-smokers. Uptake of e-cigarettes
among young non-smokers is a particular concern, given that
nicotine use in young people may disrupt brain development
with long term, irreversible consequences for brain function.19
The authors categorically dismiss the possibility that e-cigarettes
may be a gateway to smoking, arguing that even the concept of
a children’s gateway should be rejected. This view seems
premature, particularly given recently emerging evidence20 such
as an American study, published after the PHE report, which
concluded that “those who had ever used e-cigarettes at baseline
compared with nonusers were more likely to report initiation
of combustible tobacco use over the next year.”21 Furthermore,
none of the research so far can be considered conclusive, and
longer term studies are needed.
Evidence on the risk of e-cigarette aerosol to bystanders in
enclosed public spaces is sparse. However, the PHE report seems
to equate lack of evidence with evidence of lack of effect. It
claims that there is “no identified risk to bystanders,” a view
that may be premature.
The report has many other omissions, such as concerns about
product safety, including forged safety certificates reported by
a BBC Fake Britain documentary in December 2014, and the
lack of evidence of risks from long term dual use with
conventional cigarettes.22 Yet perhaps its most striking feature
is its consistent adoption of the most optimistic position on the
limited evidence available. To take one example, the report
offers reassurance that e-cigarettes when “used as intended pose
no risk of nicotine poisoning to users.” This is true, but it is
equally true of all poisons. The report rightly calls for nicotine
to be in child-proof containers given the attraction of colourful
packaging. However, it quotes a report of over 2400 poisoning
cases in the United States up to February 201423 as saying “none
resulted in any serious harm,” although the US report included
reference to a death attributed to suicide. Nor does it cite the
report’s conclusion that “the public should be aware that
e-cigarettes have the potential to cause acute adverse health
effects and represent an emerging public health concern.”
The PHE authors also fail to consider the practical consequences
of their recommendations. If e-cigarettes are so safe, presumably
there will be no restriction on using them in cars. This will make
the forthcoming ban on smoking in cars with children virtually
unenforceable because it will be extremely difficult to determine
what is causing a cloud of smoke or vapour in a moving car.
Finally, the PHE summary states, “The accuracy of nicotine
content labelling currently raises no major concerns.” Surely,
England’s leading public health agency cannot be indifferent
to a situation where consumer product information is known to
be wildly inaccurate?6 24
Where next for policy on e-cigarettes?
In 2016, the European Union Tobacco Products Directive25will
come into force despite some of the most intensive tobacco
industry lobbying ever seen.26 Most of the lobbying effort
concerned packaging of conventional cigarettes. However, there
was also a powerful attack on the directive’s substantial
restrictions on e-cigarettes. These restrictions will hopefully
limit the negative effect of this flawed PHE report. Meanwhile,
directors of public health and the wider community desperately
need advice on e-cigarettes that is evidence based and free from
any suspicion of influence by vested interests.
Happily, a consensus may be emerging. The English chief
medical officer (CMO) recently said that, if e-cigarettes have a
role in smoking cessation that should be as “licensed medicines.
This would provide assurance on the safety, quality, and efficacy
to consumers who want to use these products as quitting aids.”27
That would, of course, require data to show that they were both
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safe and effective because, as the CMO also notes, “there
continues to be a lack of evidence on the long-term use of
e-cigarettes.” We agree with this view.
Competing interests: We have read and understood BMJ policy on
declaration of interests and have no relevant interests to declare.
Provenance and peer review: Not commissioned; externally peer
reviewed.
1 McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update: a report
commissioned by Public Health England. Public Health England, 2015.
2 Brimelow A. E-cigarettes could be prescribed by the NHS to help smokers quit, report
says. BBC News 2015 Aug 19. www.bbc.co.uk/news/health-33978603.
3 Royal College of Physicians of London. RCP statement on e-cigarettes. 2014. www.
rcplondon.ac.uk/press-releases/rcp-statement-e-cigarettes.
4 ASH. Electronic cigarettes 2014.www.ash.org.uk/files/documents/ASH_715.pdf.
5 World Health Organization. Electronic nicotine delivery systems. 2014. http://apps.who.
int/gb/fctc/PDF/cop6/FCTC_COP6_10Rev1-en.pdf?ua=1.
6 European Commission. E-cigarettes myth buster. 2015. http://ec.europa.eu/health/tobacco/
docs/tobacco_mythbuster_en.pdf .
7 McKee M. Electronic cigarettes: peering through the smokescreen. Postgrad Med J
2014;90:607-9.
8 Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and
mortality: a 16-year follow-up of 19,732 men and women from the Copenhagen Centre
for Prospective Population Studies. Am J Epidemiol 2002;156:994-1001.
9 Hitchman SC, Brose LS, Brown J, et al. Associations between e-cigarette type, frequency
of use, and quitting smoking: findings from a longitudinal online panel survey in Great
Britain. Nicotine Tob Res 2015:ntv078.
10 McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation
and reduction. Cochrane Database Syst Rev 2014;12:CD010216.
11 Pisinger C, Døssing M. A systematic review of health effects of electronic cigarettes.
Prevent Med 2014;69:248-60.
12 Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products
using the MCDA approach. Eur Addict Res 2014;20:218-25.
13 Moneyhouse Commercial Register and Business Information. EuroSwiss Health. 2015.
www.moneyhouse.ch/en/u/v/euroswiss_health_sa_CH-550.1.035.243-5.htm.
14 Delon Human. Tobacco Tactics 2015. www.tobaccotactics.org/index.php/Delon_Human.
15 Human D. Wise nicotine . Dennis Barber, 2010.
16 British American Tobacco. Why it matters. Sustainability focus report 2013: how we
address the public health impact of our products. 2013. www.bat.com/group/sites/UK__
9D9KCY.nsf/vwPagesWebLive/DO964UGU/$file/A_Focus_on_Harm_Reduction_Report_
2013.pdf.
17 Riccardo Polosa. Tobacco Tactics 2015. www.tobaccotactics.org/index.php/Riccardo_
Polosa.
18 Health and Social Care Information Centre. More than a fifth of young people have tried
e-cigarettes. 23 Jul 2015. www.hscic.gov.uk/article/6555/More-than-a-fifth-of-young-
people-have-tried-e-cigarettes.
19 Goriounova NA. Long-term consequences of nicotine exposure during adolescence:
synaptic plasticity in rodent and human cortical neuronal networks. PhD thesis. Vrije
Universiteit Amsterdam, 2012.
20 Chapman S. Are e-cigarettes a gateway to smoking in 14-year-olds? New US data. The
Conversation 2015 Aug 21. https://theconversation.com/are-e-cigarettes-a-gateway-to-
smoking-in-14-year-olds-new-us-data-46468.
21 Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of electronic cigarette use
with initiation of combustible tobacco product smoking in early adolescence. JAMA
2015;314:700-7.
22 Chapman S. E-cigarettes: the best and the worst case scenarios for public health-an
essay by Simon Chapman. BMJ 2014;349:g5512.
23 Chatham-Stephens K, Law R, Taylor E, et al. Notes from the field: calls to poison centers
for exposures to electronic cigarettes—United States, September 2010-February 2014.
MMWR 2014;63:292-3.
24 Yang L, Rudy SF, Cheng JM, Durmowicz, EL. Electronic cigarettes: incorporating human
factors engineering into risk assessments. Tob Contr 2014;23(suppl 2):ii47-53.
25 European Union. Directive 2014/40/EU of the European Parliament and of the Council of
3 April 2014 on the approximation of the laws, regulations and administrative provisions
of the member states concerning the manufacture, presentation and sale of tobacco and
related products and repealing directive 2001/37/EC. European Commission, 2014.
26 Peeters S, Costa H, Stuckler D, et al. The revision of the 2014 European Tobacco Products
Directive: an analysis of the tobacco industry’s attempts to “break the health silo.” Tob
Contr 2015 Feb 24. [Epub ahead of print.] doi:10.1136/tobaccocontrol-2014-051919.
27 Meikle J. Vaping: e-cigarettes safer than smoking, says Public Health England.Guardian
2015 Aug 19. www.theguardian.com/society/2015/aug/19/public-health-england-e-
cigarettes-safer-than-smoking.
Cite this as: BMJ 2015;351:h4863
© BMJ Publishing Group Ltd 2015
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;351:h4863 doi: 10.1136/bmj.h4863 (Published 15 September 2015) Page 3 of 3
ANALYSIS
Key messages
Public Health England’s endorsement of the safety and efficacy of e-cigarettes is based on uncertain evidence
The quality of evidence that e-cigarettes help smokers to quit is weak
Recent evidence questions the conclusion that e-cigarettes are not a gateway to smoking
Until better evidence is available public health strategies should follow the precautionary principle
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